上海复宏汉霖生物技术股份有限公司 Henlius
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Henlius and SVAX Forge Strategic Partnership in the MENAT Market 2024-11-09 00:35
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer 2024-09-21 13:42
Henlius Trastuzumab Receives FDA Approval in the United States 2024-04-29 20:18
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity 2024-04-17 20:32
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved 2024-03-21 19:47
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development 2024-03-04 21:28
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development 2024-03-04 21:19
First International Shipment of HANSIZHUANG Launched 2024-01-25 21:41
First International Shipment of HANSIZHUANG 2024-01-25 20:45
HANSIZHUANG Sets Sail in Indonesia Market 2023-12-28 21:51
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA 2023-12-12 20:30
Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved 2023-11-15 20:16
Henlius Announces NMPA Approvals of Two ADC Candidates for IND 2023-10-27 20:16
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India 2023-10-27 19:47
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India 2023-10-27 19:13
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe 2023-10-25 21:15
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC 2023-09-25 07:41
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA 2023-09-12 19:24
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth 2023-08-25 19:26
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements 2023-07-28 15:53
1 2 3